denkapparat Operations GmbH Takes $215,000 Position in IQVIA Holdings Inc. (NYSE:IQV)

denkapparat Operations GmbH purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 1,092 shares of the medical research company’s stock, valued at approximately $215,000.

Several other institutional investors have also recently bought and sold shares of the business. Intech Investment Management LLC acquired a new stake in shares of IQVIA in the third quarter valued at $223,000. Algert Global LLC bought a new stake in IQVIA during the 3rd quarter worth about $514,000. Larson Financial Group LLC increased its position in IQVIA by 745.1% in the 3rd quarter. Larson Financial Group LLC now owns 431 shares of the medical research company’s stock valued at $102,000 after acquiring an additional 380 shares in the last quarter. Fisher Asset Management LLC raised its stake in shares of IQVIA by 4.8% in the third quarter. Fisher Asset Management LLC now owns 7,398 shares of the medical research company’s stock worth $1,753,000 after acquiring an additional 341 shares during the last quarter. Finally, Private Trust Co. NA grew its stake in shares of IQVIA by 10.7% during the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after purchasing an additional 47 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV opened at $177.27 on Friday. The firm’s 50 day moving average price is $193.15 and its two-hundred day moving average price is $206.47. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a twelve month low of $176.03 and a twelve month high of $253.84. The firm has a market cap of $31.25 billion, a P/E ratio of 23.64, a PEG ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

IQV has been the topic of several research reports. Citigroup reduced their price objective on IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Robert W. Baird decreased their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. William Blair reissued an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Finally, Morgan Stanley increased their price objective on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.